Jenburkt Pharmaceuticals Ltd. reported unaudited standalone earnings results for the third quarter and nine months December 31, 2013. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 194.838 million against INR 176.280 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 27.689 million against INR 18.703 million a year ago. Profit from ordinary activities before tax was INR 27.041 million against INR 21.600 million a year ago. Net profit was INR 19.541 million or INR 4.20 per basic and diluted share against INR 14.400 million or INR 3.10 per basic and diluted share a year ago.

For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 562.68 million against INR 520.785 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 76.337 million against INR 64.859 million a year ago. Profit from ordinary activities before tax was INR 72.465 million against INR 64.640 million a year ago. Net profit was INR 51.965 million or INR 11.18 per basic and diluted share against INR 45.440 million or INR 9.77 per basic and diluted share a year ago.